PRADIGASTAT

/static/temp/default.svg

Search structure


Synonyms	LCQ-908-NXA LCQ-908NXA LCQ908-NXA Lcq-908 Lcq908 - dgat-1-inhibitor Pradigastat
Status
Molecule Category	UNKNOWN
UNII	2U23G6VNUZ


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GXALXAKNHIROPE-QAQDUYKDSA-N
Smiles	O=C(O)C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1
InChI	InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)/t16-,17-

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C25H24F3N3O2
Molecular Weight	455.48
AlogP	6.65
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	6.0
Polar Surface Area	75.11
Molecular species	ACID
Aromatic Rings	3.0
Heavy Atoms	33.0

Bioactivity

Mechanism of Action	Action	Reference
Diacylglycerol O-acyltransferase 1 inhibitor	INHIBITOR	PubMed PubMed


Protein: Diacylglycerol O-acyltransferase 1 Description: Diacylglycerol O-acyltransferase 1 Organism : Homo sapiens O75907 ENSG00000185000

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Transferase	71	55	-	-	-

Assay Description	Organism	Bioactivity	Reference
Reduction in fasting triglyceride levels in familial chylomicronemia syndrome patient at 20 mg dosed daily	Homo sapiens	40.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-3.82 %
Inhibition of recombinant human his-tagged DGAT1 expressed in Sf9 insect cells using oleoyl-CoA and diolein as substrates incubated for 30 mins by LC/MS/MS analysis	Homo sapiens	55.0 nM
Inhibition of DGAT1 in mouse C2C12 cells assessed as reduction in intracellular triglyceride production incubated for 2 hrs in presence of BSA-complexed oleate by LC/MS/MS analysis	Mus musculus	71.0 nM
Antihyperlipidemic activity in Sprague-Dawley rat lipid bolus model assessed as reduction in plasma triglyceride excursion at 5 mg/kg, po administered via gavage 4 hrs prior to lipid challenge and measured upto 8 hrs post compound dose by GPO-Trinder method relative to control	Rattus norvegicus	50.0 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	-9.244 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.02 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.02 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2364624
DrugBank	DB12866
FDA SRS	2U23G6VNUZ
Guide to Pharmacology	7830
PubChem	53387035
SureChEMBL	SCHEMBL1289309

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).